In the current study, we show that genetic ablation of kindlin-2 is sufficient to inhibit the increases of the levels of PYCR1, proline, and collagen matrix in lung adenocarcinoma and reduces tumor burden and mortality rate in vivo (Fig. 9, 10). The gene discussed is FERMT2; the disease is lung adenocarcinoma.